/
A leading provider of cancer screening and diagnostic tests, Exact Sciences Corporation (together with its subsidiaries, Exact, we, us, our or the Company ) gives patients and health care professionals the clarity needed to take life-changing action earlier. Building on the success of the Cologuard and Oncotype DX tests, we are investing in our pipeline to develop innovative solutions for use b…
The business is unprofitable at the operating level (-6.35% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 17.7% YoY with margins expanding 31.7pp.
Net debt of $1.57B represents 4.4x FCF, leverage limits flexibility.
Profitability & Returns
Revenue (TTM)
$3.25B
▲ +17.7% YoY
Net Income (TTM)
-$208M
▲ +79.8% YoY
Op. Margin
-6.35%
▲ +31.7pp YoY
ROIC
-3.30%
▲ +16.6pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$357M
▲ +378.6% YoY
Op. Cash Flow (TTM)
$491M
▲ +133.4% YoY
Net Debt
$1.57B
Cash & Equiv.
$965M
5Y CAGR: +16.8%
5Y CAGR: +38.0%
Continue Research